BioCentury
ARTICLE | Clinical News

Tracleer bosentan: Preliminary Phase III data

March 8, 2010 8:00 AM UTC

Preliminary data from the double-blind, international Phase III BUILD-3 trial in 616 patients showed that 125 mg twice-daily Tracleer missed the primary endpoint of significantly reducing time to occu...